Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 475 people with a type of slow-growing blood cancer called indolent non-Hodgkin lymphoma. Participants were divided into two groups: 320 people received idelalisib combined with two chemotherapy medicines (bendamustine and rituximab), while 155 people received a placebo (an inactive dummy treatment) combined with the same two chemotherapy medicines. The trial was measuring how long people went without their cancer getting worse (called "progression-free survival"), as well as how many people's cancer responded to treatment and how long people lived overall. The reported data shows that no numerical results were submitted to ClinicalTrials.gov for any of the outcome measures — including progression-free survival, overall response rate, complete response rate, lymph node response rate, or overall survival. This means that figures for these measurements were not reported in the structured results data available on the registry. Of the participants who started the trial, 53 people in the idelalisib group and 45 people in the placebo group were recorded as having completed it, with the remaining participants noted as not completing the trial; however, no outcome measurement numbers accompanied these figures. Because no outcome data was submitted for either group across any of the planned measures, it is not possible to describe what the trial found in terms of numbers. The reported data shows only that the trial took place and recorded participation figures, but the specific results were not available in the registry entry. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Lymphoma Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of slow-growing B-cell lymphoma (a blood cancer), confirmed by a tissue sample test.
- Your specific type of lymphoma must be one of the following: Follicular Lymphoma (Grade 1, 2, or 3a), Small Lymphocytic Lymphoma (SLL), Lymphoplasmacytoid Lymphoma or Waldenström Macroglobulinemia, or Marginal Zone Lymphoma (in the spleen, lymph nodes, or other areas).
Who may not be able to join:
- You have a history of a different type of lymphoma or blood cancer not listed in the eligible types above.
- You currently have or have had certain liver or bile-related conditions, including drug-related liver damage, active hepatitis B or C, alcoholic liver disease, liver scarring (cirrhosis), high blood pressure in the liver, or related conditions (confirm with trial site).
- You were previously treated with a drug called bendamustine and it did not work for you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gilead Study Director, Gilead Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.